呈交日期： 2025年10月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | ...

Core Points - Weigao Group has signed a non-binding letter of intent to acquire 100% equity of Weigao Puri through Weigao Blood Purification [1] - Weigao Blood Purification specializes in the research, production, and sales of medical products for blood purification, including hemodialysis devices and peritoneal dialysis solutions [1] - Weigao Puri focuses on the development and production of pre-filled drug delivery systems and automatic safety drug delivery systems, providing comprehensive drug delivery solutions for global biopharmaceutical companies [1] Business Synergy - The potential transaction is expected to create business synergies between Weigao Puri and Weigao Blood Purification, further expanding the overall business landscape of the group [2]

Group 1 - The core point of the news is that Weigao Co., Ltd. has signed a non-binding letter of intent for a potential acquisition of 100% equity in Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. by issuing consideration shares to its shareholders [1] - The potential transaction involves Weigao Blood Purification, which is primarily engaged in the research, production, and sales of medical products for blood purification, including hemodialysis devices and peritoneal dialysis solutions [1] - As of the announcement date, Weigao Blood Purification is controlled by Weigao Group Co., Ltd., with Weigao Co., Ltd. holding a 23.53% stake in Weigao Blood Purification [1] Group 2 - Weigao Purui focuses on the research, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems, aiming to provide comprehensive drug delivery solutions for global biopharmaceutical companies [2] - As of the announcement date, Weigao Purui is a non-wholly owned subsidiary of Weigao Co., Ltd., with ownership stakes of 94.0706%, 4.0215%, and 1.9078% held by Weigao Co., Ltd., Weihai Shengxi, and Weihai Ruiming, respectively [2] Group 3 - Related events include the potential injection of Weigao Blood Purification into Weigao Purui and the resignation of Yan Xia as Vice Chairman and Non-Executive Director of Weigao Co., Ltd. [3]

威高股份(01066)公布，于2025年10月17日，公司、威海盛熙企业管理咨询中心(有限合伙)(威海盛熙)、 威海瑞明企业管理咨询合伙企业(有限合伙)(威海瑞明)及山东威高血液净化制品股份有限公司(威高血净) 签订了一份不具法律约束力的意向书，据此威高血净向各威高普瑞股东发行对价股份以收购威高普瑞 100%的股权。 威高普瑞聚焦预灌封给药系统及自动安全给药系统等医药包材的研发、生产与销售，致力于为全球生物 制药企业提供一站式药品递送整体解决方案。截至本公告日期，威高普瑞为公司的非全资附属公司，由 公司、威海盛熙和威海瑞明分别持有94.0706%、4.0215%及1.9078%的股权。 董事会认为，潜在交易若可完成，威高普瑞与威高血净在业务上将产生协同效应，集团整体业务版图将 进一步扩大。 MACD金叉信号形成，这些股涨势不错！ 据悉，威高血净是一家在中国设立的公司，其A股在上海证券交易所上市(证券代码：603014.SH)。该公 司主要从事血液净化医用制品的研发、生产和销售，主要产品包括血液透析器、血液透析管路、血液透 析机以及腹膜透析液，分别围绕血液透析和腹膜透析领域，辅以透析配套产品的销售。截至本公告日 ...

Core Viewpoint - Weigao Group has signed a non-binding letter of intent for a potential acquisition of 100% equity in Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd by Weigao Blood Purification Products Co., Ltd, indicating strategic expansion in the pharmaceutical packaging sector [1][2] Group 1: Company Overview - Weigao Blood Purification Products Co., Ltd is primarily engaged in the research, production, and sales of medical products for blood purification, including hemodialyzers, blood dialysis tubing, dialysis machines, and peritoneal dialysis solutions [1] - As of the announcement date, Weigao Blood Purification is controlled by Weigao Group, which holds a 23.53% direct stake in the company [1] Group 2: Weigao Purui Overview - Weigao Purui focuses on the research, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems, aiming to provide comprehensive drug delivery solutions for global biopharmaceutical companies [2] - Weigao Purui is a non-wholly owned subsidiary of the company, with ownership stakes of 94.0706% by the company, 4.0215% by Weihai Shengxi, and 1.9078% by Weihai Ruiming [2]

Group 1 - Weigao Group has signed a non-binding letter of intent for a potential acquisition of 100% equity in Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd by Weigao Blood Purification [1] - The potential transaction involves issuing consideration shares to Weigao Purui shareholders, which include Weigao Group and its affiliates [1] - Weigao Blood Purification is primarily engaged in the research, production, and sales of medical products for blood purification, including hemodialysis devices and peritoneal dialysis solutions [1] Group 2 - Weigao Purui focuses on the research, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems, providing comprehensive drug delivery solutions for global biopharmaceutical companies [2] - As of the announcement date, Weigao Purui is a non-wholly owned subsidiary of the company, with ownership stakes of 94.0706%, 4.0215%, and 1.9078% held by the company, Weihai Shengxi, and Weihai Ruiming, respectively [2]

山東威高集團醫用高分子製品股份有限公 司 Shandong Weigao Group Medical Polymer Company Limited * （在中華人民共和國註冊成立的股份有限公司） （股份代號：1066） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 威高普瑞聚焦預灌封給藥系統及自動安全給藥系統等醫藥包材的研發、生產 與銷售，致力於為全球生物製藥企業提供一站式藥品遞送整體解決方案。截 至本公告日期，威高普瑞為本公司的非全資附屬公司，由本公司、威海盛熙和 威海瑞明分別持有94.0706%、4.0215%及1.9078%的股權。 董事會認為，潛在交易若可完成，威高普瑞與威高血淨在業務上將產生協同 效應，本集團整體業務版圖將進一步擴大。 上市規則涵義 自願公告 本公告乃由山東威高集團醫用高分子製品股份有限公司（「本公司」，連同其附 屬公司合稱「本集團」）自願刊發。 潛在交易 本公司董事會（「董事會」）謹此宣佈，於2025年10月17日（ ...

山東威高集團醫用高分子製品股份有限公司章程 山東威高集團醫用高分子製品股份有限公司 章 程 二零二五年十月十七日 | | | | 第一章 總則-------------------------------------------------------------------------------------------- 1 | | --- | | 第二章 經營宗旨和範圍----------------------------------------------------------------------------- 2 | | 第三章 股份-------------------------------------------------------------------------------------------- 3 | | 第四章 股東和股東會-------------------------------------------------------------------------------- 9 | | 第五章 董事會------------------------------ ...

EF001 | | 非居民企業 | | | | --- | --- | --- | --- | | | | | 對於H股股東為境外非居民企業 | | | （非中國內地登記地址） | 10% | （包括香港中央結算（代理人）有 | | | | | 限公司、其他代理人、代理人或受 | | | | | 托人或其他組織），本公司將按照 | | | | | 股息的10%的稅率代扣代繳企業所 | | | | | 得稅。 | | | 非個人居民 | | | | | （非中國內地登記地址） | 10% | H股個人股東為香港或澳門居民， | | | | | 且住所地為與中國簽訂10%股息稅 | | | | | 率的稅收協定的國家，本公司將按 | | | | | 照股息的 10% 的稅率代扣代繳個 | | | | | 人所得稅。 | | | 境內個人投資者及證券投資基 | 20% | 對於註冊地址在中國境內的H股個 | | | 金通過滬港通、深港通投資本 | | 人股東，本公司將按照股息的20% | | | 公司H股股 | | 的稅率代扣代繳個人所得稅。 | | 發行人所發行上市權證/可轉換債券的相關信息 | | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 山東威高集團醫用高分子製品股份有限公 司 Shandong Weigao Group Medical Polymer Company Limited * （在中華人民共和國註冊成立的股份有限公司） （股份代號：1066） 於二零二五年十月十七日舉行之 股東特別大會之投票表決結果 及 中期股息付款 摘要 1 * 僅供識別 股東特別大會之投票表決結果 股東特別大會通告所載之所有決議案均已按投票表決方式獲通過。各決議案 之投票表決結果如下： | | 普通決議案 | 票數及佔總票數之 | | | --- | --- | --- | --- | | | | 概約百分比(%) | | | | | 贊成 | 反對 | | 1. | 審議及批准二零二五年H股激勵計劃及計 | 3,594,554,305 | 92,928,933 | | | 劃授權限額。 | (97.48%) | (2.52%) | | 2. | 審議及 ...